SFI
EVLO

Susquehanna Fundamental Investments’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

Susquehanna Fundamental Investments’s Portfolio EVLO Stock Details EVLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$44K Sell
654
-576
-47% -$47.9K ﹤0.01% 1497
2021
Q4 		$149K Buy
+1,230
New +$208K ﹤0.01% 1294

Other funds holding EVLO

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna Fundamental Investments's EVLO Position: Q1 2022 in Review

Susquehanna Fundamental Investments reduced its Evelo Biosciences, Inc. Common Stock (EVLO) stake by 47% in Q1 2022, selling an estimated $47.9K and leaving 654 shares worth $44K. The position accounts for ﹤0.01% of the portfolio, ranked #1497.

Susquehanna Fundamental Investments first reported a position in EVLO in Q4 2021 and has held it in 2 quarters since. The position peaked at $149K in Q4 2021. 68 funds tracked by Wall St. Rank hold EVLO as of Q1 2022.

  • Susquehanna Fundamental Investments held 654 shares of Evelo Biosciences, Inc. Common Stock worth $44K as of Q1 2022.
  • Susquehanna Fundamental Investments sold 576 Evelo Biosciences, Inc. Common Stock shares in Q1 2022, an estimated $47.9K.
  • Evelo Biosciences, Inc. Common Stock made up ﹤0.01% of Susquehanna Fundamental Investments's portfolio in Q1 2022, its #1497 holding.
  • Susquehanna Fundamental Investments first reported a position in Evelo Biosciences, Inc. Common Stock in Q4 2021 and has held it in 2 quarters since.
  • Susquehanna Fundamental Investments's Evelo Biosciences, Inc. Common Stock position peaked at $149K in Q4 2021.
  • 68 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q1 2022.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2022, filed 16 May 2022.